Advertisement

Documenta Ophthalmologica

, Volume 116, Issue 1, pp 57–60 | Cite as

Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy

  • Irena Tsui
  • Daniel Casper
  • Chai Lin Chou
  • Stephen H. Tsang
Case Report

Abstract

Topiramate is known to cause ocular side effects such as refractive changes and angle closure. We describe a patient with an electronegative electroretinogram (ERG) which may have been related to topiramate use. Electronegative ERG’s have been associated with other drugs in humans as well as topiramate use in rabbits. However, this would be the first suggestion of causality in humans.

Keywords

Electronegative Electroretinogram Topiramate Topamax Best disease Vitelliform maculopathy 

Notes

Acknowledgements

We greatly appreciate the assistance of the Division of Medical Illustration and Neeco Palmer for sharing of advice, ideas, and equipment. We would also like to thank the patient for her cooperation. SHT is a Burroughs-Wellcome Program in Biomedical Sciences Fellow, and is also supported by the Charles E. Culpeper Scholarship, Foundation Fighting Blindness, Hirschl Trust, Schneeweiss Stem Cell Fund, Joel Hoffmann Scholarship, Jonas Family Fund, Jahnigen-Hartford-American Geriatrics Society, Eye Surgery Fund, Bernard Becker-Association of University Professors in Ophthalmology-Research to Prevent Blindness (RPB), and NIH grant EY004081.

References

  1. 1.
    Tsui I, Song B, Lin CS, Tsang S 2007 A practical approach to retinal dystrophy. Retinal Physician 4:18–26Google Scholar
  2. 2.
    Theischen M, Schilling H, Steinhorst UH 1997 EOG in adult vitelliform macular degeneration, butterfly-shaped pattern dystrophy and Best disease. Ophthalmologe 9:230–233CrossRefGoogle Scholar
  3. 3.
    Glacet-Bernard A, Soubrane G, Coscas G 1990 Macular vitelliform degeneration in adults. Retrospective study of a series of 85 patients. J Fr Ophtalmol 13:407–420PubMedGoogle Scholar
  4. 4.
    Heckenlively JR, Arden GB 2006 Principles and practice of clinical electrophysiology of vision, 2nd edn. Cambridge, Mass, MIT Press, 809–822Google Scholar
  5. 5.
    Kjellstrom S, Bruun A, Isaksson B, Eriksson T, Andreasson S, Ponjavic V 2006 Retinal function and histopathology in rabbits treated with Topiramate. Doc Ophthalmol 113:179–186PubMedCrossRefGoogle Scholar
  6. 6.
    Asensio-Sanchez VM, Torreblanca-Aguera B, Martinez-Calvo S, Calvo MJ, Rodriguez R 2006 Severe ocular side effects with Topamax. Arch Soc Esp Oftalmol 81:345–348PubMedGoogle Scholar
  7. 7.
    White HS. 2005 Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 45:S48–S56PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Irena Tsui
    • 1
    • 2
  • Daniel Casper
    • 2
  • Chai Lin Chou
    • 1
    • 3
  • Stephen H. Tsang
    • 1
    • 3
  1. 1.Brown Glaucoma Laboratory at Edward S. Harkness Eye InstituteColumbia UniversityNew YorkUSA
  2. 2.Edward S. Harkness Eye InstituteColumbia UniversityNew YorkUSA
  3. 3.Department of Pathology & Cell Biology, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations